Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Imatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 known ✓ | P00519 | 20/20 | 0.98 |
| ▸ | BCR known ✓ | P11274 | 14/20 | 0.98 |
| ▸ | KIT known ✓ | P10721 | 12/20 | 0.98 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.98 |
| ▸ | ABL2 | P42684 | 7/20 | 0.98 |
| ▸ | PDGFRA | P16234 | 3/20 | 0.98 |
| ▸ | LYN | P07948 | 3/20 | 0.98 |
| ▸ | SRC | P12931 | 2/20 | 0.98 |
| ▸ | SYK | P43405 | 2/20 | 0.98 |
| ▸ | PLK4 | O00444 | 1/20 | 0.98 |
| ▸ | DDX3X | O00571 | 1/20 | 0.98 |
| ▸ | GAK | O14976 | 1/20 | 0.98 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.98 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.98 |
| ▸ | CA12 | O43570 | 1/20 | 0.98 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.98 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.98 |
| ▸ | EGFR | P00533 | 1/20 | 0.98 |
| ▸ | CA1 | P00915 | 1/20 | 0.98 |
| ▸ | CA2 | P00918 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imatinib SCHEMBL662170 | 1.00 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2929858 | 1.00 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL662077 | 0.99 | ABL1 (0.97) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL2236091 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29351601 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL29355523 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3827 | 0.99 | ABL1 (1.00) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL15201213 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL3138052 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA | |
| Imatinib SCHEMBL1462774 | 0.98 | ABL1 (0.98) | ABL1BCRKITABL2PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2509973-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | Arch Pharmalabs Limited (IN) | 2012-10-17 | — | — | EP | disclosed |
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | SHANGHAI PARLING PHARMATECH CO., LTD. (CN) | 2011-12-15 | — | — | US | disclosed |
| WO-2011070588-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | ARCH PHARMALABS LIMITED (IN) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306763-A1 | PROCESS FOR THE PREPARATION OF IMATINIB AND SALTS THEREOF | ABL1, JAK2, ABL2 | ABL1 1/4885BCR 9/4885KIT 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.